Multi-Cancer Early Detection (MCED)
This article is a placeholder. Only its topic and title are committed at this stage; the substantive body will be drafted in a future cycle of the engine.
Liquid-biopsy blood tests (Galleri, OneTest, GRAIL-class assays) detecting cell-free DNA methylation signatures across 50+ cancers. The PATHFINDER and SYMPLIFY studies define current sensitivity, specificity, and the workup-burden trade-off.